Trade Report: Today, Zacks: Second Sight Medical Products Inc. (EYES) Given $16.00 Consensus Target Price by Analysts

Today, Zacks: Second Sight Medical Products Inc. (EYES) Given $16.00 Consensus Target Price by Analysts

Second Sight Medical Products Inc. (NASDAQ:EYES) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus target price of $16.00 for the company and are anticipating that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also given Second Sight Medical Products an industry rank of 102 out of 265 based on the ratings given to related companies.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Second Sight Medical Products in a research report on Thursday, October 27th.

A number of large investors have recently bought and sold shares of EYES. Schwab Charles Investment Management Inc. boosted its stake in shares of Second Sight Medical Products by 11.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 40,984 shares of the medical device company’s stock valued at $147,000 after buying an additional 4,135 shares during the period. Alliancebernstein L.P. boosted its stake in shares of Second Sight Medical Products by 20.2% in the second quarter. Alliancebernstein L.P. now owns 33,900 shares of the medical device company’s stock valued at $121,000 after buying an additional 5,700 shares during the period. Granite Investment Partners LLC boosted its stake in shares of Second Sight Medical Products by 5.0% in the third quarter. Granite Investment Partners LLC now owns 141,206 shares of the medical device company’s stock valued at $497,000 after buying an additional 6,782 shares during the period. Psagot Investment House Ltd. boosted its stake in shares of Second Sight Medical Products by 16.6% in the second quarter. Psagot Investment House Ltd. now owns 55,362 shares of the medical device company’s stock valued at $198,000 after buying an additional 7,878 shares during the period. Finally, BlackRock Investment Management LLC boosted its stake in shares of Second Sight Medical Products by 19.1% in the second quarter. BlackRock Investment Management LLC now owns 50,314 shares of the medical device company’s stock valued at $180,000 after buying an additional 8,073 shares during the period. 7.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of Second Sight Medical Products (NASDAQ:EYES) opened at 2.05 on Monday. The company’s market cap is $86.60 million. The company has a 50 day moving average of $2.54 and a 200 day moving average of $3.43. Second Sight Medical Products has a 1-year low of $1.71 and a 1-year high of $7.70.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Wednesday, November 2nd. The medical device company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. The business had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $2.36 million. Second Sight Medical Products had a negative net margin of 502.22% and a negative return on equity of 121.31%. The firm’s revenue was down 45.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) EPS. Equities analysts expect that Second Sight Medical Products will post ($0.76) earnings per share for the current fiscal year.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Related posts

Leave a Comment